Conatumumab
- Generic Name
- Conatumumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 896731-82-1
- Unique Ingredient Identifier
- 1P48L61KM0
- Background
Conatumumab has been used in trials studying the treatment of Sarcoma, Lymphoma, Oncology, Colon Cancer, and Rectal Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
'It was just so quick': New drug to help patients like Mark before it's too late
A pre-clinical study by HRI found Conatumumab effectively treats PAD by growing new blood vessels, bypassing blockages, and restoring blood flow.
Cancer Drug May Help Save Limbs in Peripheral Artery Disease
HRI researchers found Conatumumab, a cancer drug, can treat Peripheral Artery Disease by growing new blood vessels, bypassing blockages, and restoring blood flow, potentially saving limbs and lives.
Cancer drug could be used to save the limbs of peripheral artery disease patients
Researchers at the Heart Research Institute found that Conatumumab, a cancer drug, can treat peripheral artery disease by growing new blood vessels, bypassing blockages, and restoring blood flow, potentially saving limbs and lives.
Cancer Drug Breakthrough Boosts Heart Patient Hopes
Associate Professor Mary Kavurma's pre-clinical discovery of Conatumumab for PAD paves the way for human trials, leveraging existing safety data from its use as a cancer drug. This breakthrough is part of HRI's commitment to PAD research, with the Centre for PAD collaborating with major hospitals and the University of Sydney.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath